CKD affects around 15% of adults aged 35 and over in England, roughly 1 in 7
In overseas Phase III trials (such as SURMOUNT-1), at 72 weeks, body weight decreased significantly compared to the placebo group, with the maximum 15mg dose group achieving an average reduction of -21.8kg (approximately 20% of body weight)
Microcurrent therapy is ideal for people experiencing: Mild to moderate facial sagging Loss of tone or dullness Hollowed areas post-weight loss It can also be used preventatively during your weight loss journey to help maintain structure as the fat beneath the skin decreases
As always, consult with your healthcare provider before starting any new supplement or nutrition program, especially if you are pregnant, nursing, taking medication, or have a medical condition
Urinary tract infections (UTIs) are not among the primary adverse effects highlighted in published retatrutide trial data to date